BCLI - Brainstorm Cell Therapeutics Inc.
| Previous Close | 3.8200 |
| Open | 3.8300 |
| Bid | 3.5000 x 1800 |
| Ask | 4.7400 x 800 |
| Day's Range | 3.7550 - 3.9809 |
| 52 Week Range | 2.9200 - 5.3500 |
| Volume | 48,581 |
| Avg. Volume | 69,950 |
| Market Cap | 81.449M |
| Beta (3Y Monthly) | 0.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6970 |
| Earnings Date | Jul 8, 2019 - Jul 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.50 |
- Zacks Small Cap Research•17 days ago
BCLI: Two Abstracts to be Presented at AAN Annual Meeting…
On March 28, 2019, BrainStorm Cell Therapeutics, Inc. (BCLI) announced that two abstracts have been selected for presentation at the 71st American Academy of Neurology (AAN) Annual Meeting, which is being held May 4-10, 2019. The presentations focus on biomarker correlations with clinical outcomes in the phase 2 study and the genetic characterization of neurotrophic factor production in NurOwn®, one of which was selected for oral presentation during the ‘Emerging Science Session’. On March 13, 2019, BrainStorm Cell Therapeutics, Inc. (BCLI) held a conference call to announce that the Israeli Ministry of Health has approved the company’s application for the Hospital Exemption (HE) program, which will allow for the treatment of 13 amyotrophic lateral sclerosis (ALS) patients with NurOwn®.
- GlobeNewswire•25 days ago
Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting
NEW YORK, March 28, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
- GlobeNewswire•26 days ago
BrainStorm Announces Grant of an additional New European Patent for NurOwn®
NEW YORK, March 26, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today.
- GlobeNewswire•last month
Atlas Blockchain Announces Definitive Agreement for the Acquisition of Isracann and Amendment to Investor Services Agreement
Atlas Blockchain Group Inc. (CSE:AKE) (A49.F) (ATLEF) (the “Company” or “Atlas”) is pleased to announce, further to its news release on October 11, 2018, the Company has entered into a definitive share exchange agreement dated March 12, 2019 (the “Share Exchange Agreement”), pursuant to which the Company has agreed to acquire all of the issued and outstanding common shares (the “Isracann Shares”) in the capital of Isracann Biosciences Inc. (“Isracann”), a private British Columbia company, from the shareholders of Isracann (the “Isracann Shareholders”), subject to the conditions set out in the Share Exchange Agreement (the “Transaction”).
- Zacks Small Cap Research•last month
BCLI: Hospital Exemption Approved in Israel; First Patient Enrolled in Phase 2 Study in Progressive MS…
On March 13, 2019, BrainStorm Cell Therapeutics, Inc. (BCLI) held a conference call to announce that the Israeli Ministry of Health has approved the company’s application for the Hospital Exemption (HE) program, which will allow for the treatment of 13 amyotrophic lateral sclerosis (ALS) patients with NurOwn®. The patients to be treated were selected based on separate inclusion/exclusion criteria than is being used for the ongoing Phase 3 trial of NurOwn® in ALS. BrainStorm is continuing to enroll patients in the Phase 3 clinical trial of NurOwn® (NCT03280056) for the treatment of ALS.
- GlobeNewswire•last month
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
NEW YORK and CLEVELAND, March 14, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly.
- Simply Wall St.•last month
Breakeven On The Horizon For Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Brainstorm Cell Therapeutics Inc.'s (NASDAQ:BCLI): Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to addressRead More...
- Benzinga•last month
The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 11) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
- GlobeNewswire•2 months ago
BrainStorm to Host Business Update Conference Call
NEW YORK, March 07, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
- GlobeNewswire•2 months ago
BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study
NEW YORK and CLEVELAND, Feb. 22, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly.
- GlobeNewswire•2 months ago
BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland
ZURICH, Switzerland and NEW YORK, Feb. 21, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly.
- GlobeNewswire•2 months ago
BrainStorm Issues a Statement to Patients and Shareholders
Brainstorm stays fully committed to advance our pivotal phase 3 ALS trial towards a BLA submission. We strongly believe that currently this is the best and most credible pathway to demonstrate that NurOwn® may be a safe and an effective treatment option for ALS patients. If the outcome of the trial is successful, we hope to be able to bring a much-needed solution to ALS patients as quickly as possible.
- GlobeNewswire•2 months ago
BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium
NEW YORK, Feb. 04, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
- GlobeNewswire•3 months ago
BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida
NEW YORK, Jan. 25, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
- GlobeNewswire•3 months ago
BrainStorm Granted Additional Patent for NurOwn® in Israel
NEW YORK, Jan. 22, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative.
- GlobeNewswire•3 months ago
BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
NEW YORK and IRVINE, Calif., Jan. 11, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly.
- Zacks Small Cap Research•3 months ago
BCLI: Initiating Phase 2 Study in Progressive Multiple Sclerosis…
On December 17, 2018, BrainStorm Cell Therapeutics, Inc. (BCLI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for testing NurOwn® in patients with progressive multiple sclerosis (MS). The company also announced that it has contracted with the Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute to expand production of NurOwn to support both the Phase 2 trial in MS as well as support ongoing production for the ongoing Phase 3 trial in amyotrophic lateral sclerosis (ALS).
- GlobeNewswire•4 months ago
BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week
NEW YORK, Jan. 03, 2019 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today.
- GlobeNewswire•4 months ago
BrainStorm Issues 2018 Letter to Shareholders
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders. This past year was an extraordinary success for BrainStorm Cell Therapeutics from a research and development, clinical, financial and corporate perspective.
- GlobeNewswire•4 months ago
BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial
NEW YORK and BOSTON, Dec. 26, 2018 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases,.
- GlobeNewswire•4 months ago
FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of NurOwn® for the treatment of progressive multiple sclerosis (MS). There are currently no FDA approved autologous cellular therapies addressing MS or other neurological diseases.
- Reuters•4 months ago
BrainStorm gets FDA okay for stem cell trial in MS patients
BrainStorm Cell Therapeutics Inc has received approval from the U.S. Food and Drug Administration to begin a clinical trial of its experimental stem cell treatment in patients with progressive multiple sclerosis. BrainStorm said on Monday it expects to start the U.S. Phase 2 trial in the first quarter of 2019. The U.S.-Israeli company is already studying its treatment called NurOwn in patients with the neurodegenerative disease amyotrophic lateral sclerosis (ALS) and expects to have advanced Phase 3 trial results at the end of 2019 or early 2020.
- GlobeNewswire•5 months ago
BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND
NEW YORK, Dec. 04, 2018 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating.
- Simply Wall St.•5 months ago
Do Institutions Own Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Shares?
A look at the shareholders of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while Read More...
- GlobeNewswire•5 months ago
Detailed Research: Economic Perspectives on Stellar Biotechnologies, MAM Software Group, EverQuote, Brainstorm Cell Therapeutics, Mid-Con Energy Partners, LP, and Staffing 360 Solutions — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
